



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8739

Seiichi SAITO

Appln. No.: 10/812,357

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: March 30, 2004

For: RM2 ANTIGEN (B1,4-GAINAC-DISIALYL-LC) AS PROSTATE CANCER-
ASSOCIATED ANTIGEN

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, other than any U.S. patents and patent publications, is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/812,357

A8739

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Susan J. Mack
Registration No. 30,951

Date: May 28, 2004

Substitute for Form 1449 A & B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/812,357
Confirmation Number	Not Yet assigned
Filing Date	March 30, 2004
First Named Inventor	Seiichi SAITO
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	A8739

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		HAKOMORI S. "Aberrant Glycosylation in Tumors and Tumor-associated carbohydrate antigens" <i>Advances in Cancer Research</i> vol. 52 (1989) pp. 257-331, Academic Press, USA	
		HAKOMORI, S. "Tumor Malignancy Defined by Aberrant Glycosylation and Sphingo(glycol)lipid Metabolism" <i>Cancer Research</i> vol. 56 (December 1, 1996) pp. 5309-5318 Pacific Northwest Research Foundation, Biomembrane Division, Seattle, Washington,	
		SEIICHI SAITO, SEIICHI ORIKASA, CHIKARA OHYAMA, MAKOTO SATOH and YASUO FUKUSHI "Changes in Glycolipids in Human Renal-cell Carcinoma and Their Clinical Significance" <i>Int J. Cancer</i> vol. 49 (1991) pp. 329-334, Wiley-Liss, Inc.	
		SEIICHI SAITO, STEVEN B. LEVERY, MARY ELLEN K. SALYAN, ROBERT I. GOLDBERG and SEN-ITIROH HAKOMORI "Common Tetrasaccharide Epitop NeuAca2→3Galβ1→3(NeuAca2→6)GalNAc, Presented by Different Carrier Glycosylceramides or O-Linked Peptides, Is Recognized by Different Antibodies and Ligands Having Distinct Specificities" <i>The Journal of Biological Chemistry</i> vol. 269, No. 8, February 25, 1994, pp. 5644-5652, USA	
		AKIHIRO ITO, STEVEN B. LEVERY, SEIICHI SAITO, MAKOTO SATOH and SEN-ITIROH HAKOMORI "A Novel Ganglioside Isolated from Renal Cell Carcinoma", <i>The Journal of Biological Chemistry</i> vol. 276, No. 20, May 18, 2001, pp. 16695-16703, PBC Papers in Press, USA	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.